Novo Nordisk Redoubles Metabolic Efforts as Parkinson Divestiture and Analyst Upgrade Align
Danish drugmaker sells Parkinson cell therapy asset to focus on metabolic disease, as Hedgeye sees 52-117% upside and…
Menopause Heart Data, Oral Pill Revenue Double, and a Parkinso
Novo Nordisk: Wegovy CV risk reduction 42% in perimenopausal women, oral pill sales double forecasts, high-dose 27.7% weight…